SCHEMBL22112683

SCHEMBL22112683

COC(=O)c1c(Br)c(-c2ccc(F)cc2)c(Br)n1COCC[Si](C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 1/20 0.38
DGAT1 O75907 1/20 0.37
HTR3A P46098 1/20 0.37
GCGR P47871 1/20 0.36
MAPT P10636 2/20 0.36
MAPK14 Q16539 1/20 0.35
NPC1 O15118 2/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CASP3 P42574 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
IKBKB O14920 1/20 0.34
TP53 P04637 1/20 0.34
F11 P03951 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22112684 0.87 SLC6A3 (0.36) THRBNPSR1LMNAHTR3AGCGR
SCHEMBL30725440 0.85 NPC1 (0.33) DGAT1MAPTNPC1F11
SCHEMBL24309370 0.84 PTGS2 (0.35) THRBNPSR1LMNAHTR3AGCGR
SCHEMBL30725389 0.73 DGAT1 (0.38) DGAT1NPC1
SCHEMBL15050240 0.71 NPC1 (0.34) DGAT1MAPTNPC1F11
SCHEMBL25104434 0.71 DGAT1 (0.38) DGAT1NPC1SMN1; SMN2F11
SCHEMBL25439485 0.70 GABRA5 (0.38) NPSR1LMNADGAT1MAPTNPC1
SCHEMBL25104433 0.70 F2RL1 (0.35) DGAT1NPC1SMN1; SMN2
SCHEMBL68112 0.70 DGAT1 (0.41) DGAT1MAPTMAPK14NPC1RAB9A
SCHEMBL1244925 0.70 MAPT (0.37) THRBDGAT1MAPTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020123994-A1 2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-06-18 WO disclosed